
欧洲多发性硬化症治疗市场预测至 2027 年 - 按药物类别(免疫抑制剂和免疫调节剂)、给药途径(注射剂和口服)和分销渠道(医院药房、零售药房和电子商务)划分的 COVID-19 影响和区域分析
No. of Pages: 143 | Report Code: TIPRE00022634 | Category: Life Sciences
No. of Pages: 143 | Report Code: TIPRE00022634 | Category: Life Sciences
多发性硬化症(MS)是一种影响中枢神经系统的自身免疫性疾病。多发性硬化症是一种广泛存在的致残性神经系统疾病,大多数在 20-50 岁年龄段的人群中被诊断出来。这是一种潜在的使人衰弱的疾病,会导致身体的沟通和协调功能中断。
欧洲多发性硬化症治疗市场预计将从2019年的84.2383亿美元增至2027年的132.8111亿美元;预计 2020 年至 2027 年复合年增长率为 6.0%。市场的增长归因于一些关键驱动因素,例如人们对多发性硬化症的认识不断提高,以及创新产品的开发和推出。然而,多发性硬化症治疗的高成本阻碍了市场的增长。
近年来,人们采取了各种措施和努力来提高人们对神经系统疾病的认识和教育,这有助于患者获得适合此类疾病的药物和治疗。多发性硬化症基金会及其附属团体发起了全国多发性硬化症教育和宣传月,自 2003 年起每年三月举办该活动,以提高对该疾病的认识。该计划的目标是促进对多发性硬化症的了解,并帮助患者就其治疗做出明智的决定。此外,国家 MS 协会创建并启动了“MS Kills Connection” <连接杀死MS”该活动旨在将多发性硬化症患者、治疗多发性硬化症患者的人们以及开展活动以创造一个没有多发性硬化症的世界的人们联系起来。同样,多发性硬化症治疗市场的几家参与者正在开发和推出新产品。地理和制造能力扩张战略以及产品发布有助于公司迎合广泛的客户群。此类新产品的开发和推出正在成为欧洲多发性硬化症治疗市场的主要趋势。
欧洲的 COVID-19 病例数量不断增加。由于第二波 COVID-19 疫情,许多国家政府正在努力加强各公司生产的细胞疗法、基因疗法和再生药物。由于医务人员的多样化以及集中治疗危重患者的决定,不断增加的 COVID-19 病例影响了疾病的诊断和治疗。由于当前的大流行,许多大学和研究机构停止了临床试验,科学家们将重点转移到控制COVID-19疫情上,并努力更好地研究该病毒。因此,对 COVID-19 爆发的日益关注阻碍了市场增长。
欧洲多发性硬化症治疗市场按药物类别分为免疫抑制剂和免疫调节剂。免疫调节剂细分市场在 2019 年占据了较大的市场份额,而免疫抑制剂细分市场预计在预测期内将实现更高的复合年增长率。
欧洲多发性硬化症治疗市场按给药途径分为注射剂和口服剂。注射剂细分市场在 2019 年占据了更大的市场份额,预计该细分市场在预测期内的市场复合年增长率将更高。
基于分销渠道欧洲多发性硬化症治疗市场分为医院药房、零售药房和电子商务。医院药房细分市场在 2019 年占据最大市场份额。然而,预计电子商务细分市场在预测期内的复合年增长率最高。
一些与本报告有关的欧洲多发性硬化症治疗市场报告相关的主要和次要来源包括欧洲疾病预防和控制中心 (ECDC) 、欧洲神经病学学会 (EAN) 和欧洲药品管理局 (EMA)。
< span>
Strategic insights for Europe Multiple Sclerosis Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 8,423.83 Million |
Market Size by 2027 | US$ 13,281.11 Million |
Global CAGR (2020 - 2027) | 6.0% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By 药物类别
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Multiple Sclerosis Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Multiple Sclerosis Therapeutics Market is valued at US$ 8,423.83 Million in 2019, it is projected to reach US$ 13,281.11 Million by 2027.
As per our report Europe Multiple Sclerosis Therapeutics Market, the market size is valued at US$ 8,423.83 Million in 2019, projecting it to reach US$ 13,281.11 Million by 2027. This translates to a CAGR of approximately 6.0% during the forecast period.
The Europe Multiple Sclerosis Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Multiple Sclerosis Therapeutics Market report:
The Europe Multiple Sclerosis Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Multiple Sclerosis Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Multiple Sclerosis Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.